RxDoctor Payments DataLook up a doctor →

Rafael Rivera Rivera, MD

Critical Care Medicine · Wichita Falls, TXNPI 1669432209

Payments from drug & device makers

$16,273in general payments, 2019–2025

Across 879 payments — averaging $18.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$3K
  • AstraZeneca$3K
  • Mylan Specialty L.p.$2K
  • Boehringer Ingelheim$1K
  • Regeneron Healthcare Solutions, Inc.$959
  • Sanofi$752
  • plus $6K from 38 others

What the payments were for

  • Food & beverage$16,10299%
  • Education$1721%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,273 in reported general payments places this provider in the 90th percentile of 507 critical care medicine providers in Texas.

See all critical care medicine providers in Texas

Medicare billing

Part B allowed, 2024
$451,821
Medicare patients
685
Services billed
5,926

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate17$235,621
Trelegy ElliptaFluticasone/Umeclidin/Vilanter191$163,110
OpsumitMacitentan13$161,206
Breztri AerosphereBudesonide/Glycopyr/Formoterol71$53,960
Spiriva RespimatTiotropium Bromide51$34,924
Breo ElliptaFluticasone/Vilanterol34$25,294
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr21$15,599
Stiolto RespimatTiotropium Br/Olodaterol Hcl21$9,977
Sildenafil Citrate15$6,428
SymbicortBudesonide/Formoterol Fumarate16$5,972
Roflumilast41$4,937
Albuterol Sulfate HfaAlbuterol Sulfate83$2,669
Fluticasone-SalmeterolFluticasone Propion/Salmeterol16$1,710
Fluticasone Propionate16$1,584
Ventolin HfaAlbuterol Sulfate14$1,174

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat$1,038$280,52289 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$3,238$204,002246 claims
Actelion Pharmaceuticals US, Inc.Opsumit$596$161,20613 claims
AstraZenecaBreztri Aerosphere, Symbicort$2,593$59,93287 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 507 critical care medicine providers in Texas.

Other critical care medicine in Wichita Falls

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →